Danaher's revenue outlook cut, biotech miss overshadow profit forecast raise

Danaher raised its annual profit forecast, but premarket shares fell nearly 12% after it trimmed its core revenue growth outlook and reported weaker-than-expected biotechnology revenue. The revenue miss in biotech offset the profit guidance increase, signaling softer top-line momentum for the segment.